AgomAb Therapeutics NV (AGMB)
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the U...
- Open
- 8.650
- High
- 9.340
- Low
- 8.000
- Prev. Close
- 8.650
- Volume
- 391.63K
- Turnover
- 3.29M
- Avg Price
- 8.392
- Bid/Ask Ratio
- --
- Amplitude
- 15.49%
- 52wk High
- 17.820
- Volume Ratio
- 4.47
- Turnover Ratio
- 2.83%
- 52wk Low
- 8.000
- Float Mkt Cap
- 118.44M
- Market CapUSD
- 421.56M
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -1.92
- EPSDynamic
- -1.44
- EPSStatic
- --
- BVPS
- 2.14
- P/B
- 3.99
- Circulating Supply
- 13.84M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 49.25M
- Min lot size
- 1
- Currency
- USD
AgomAb Therapeutics NV Analyst Rating
View moreForecast & Rating
Oct 1, 2026Price forecast
$37.67340.03%
Forecast & RatingStrong buy
7analysts
- Strong buy57.14%
- Buy42.86%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · Oct 1 at 09:06 PM
12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga_article · Oct 1 at 06:31 PM
Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial
- benzinga_article · Oct 1 at 05:06 PM
12 Health Care Stocks Moving In Thursday's Intraday Session
- Quartr · Oct 1 at 10:33 AM
AGMB: Ontunisertib showed sustained safety and disease control in FSCD, supporting Phase 2b initiation
- StockTitan · Oct 1 at 02:30 AM
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease | AGMB Stock News
